251 related articles for article (PubMed ID: 28590828)
1. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study.
Ko WJ; Han HH; Ham WS; Lee HW
Aging Male; 2017 Jun; 20(2):81-88. PubMed ID: 28590828
[TBL] [Abstract][Full Text] [Related]
2. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
McVary KT; Monnig W; Camps JL; Young JM; Tseng LJ; van den Ende G
J Urol; 2007 Mar; 177(3):1071-7. PubMed ID: 17296414
[TBL] [Abstract][Full Text] [Related]
4. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
7. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Kaplan SA; Gonzalez RR; Te AE
Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
[TBL] [Abstract][Full Text] [Related]
8. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study.
Xue Z; Lin Y; Jiang Y; Wei N; Bi J
BMC Urol; 2018 Dec; 18(1):115. PubMed ID: 30545338
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
11. Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Ma C; Zhang J; Cai Z; Xiong J; Li H
Biomed Res Int; 2020; 2020():1419520. PubMed ID: 32309423
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension.
McVary KT; Kaufman J; Young JM; Tseng LJ
Int J Clin Pract; 2007 Nov; 61(11):1843-9. PubMed ID: 17887993
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Tamimi NA; Mincik I; Haughie S; Lamb J; Crossland A; Ellis P
BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
15. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
18. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
19. Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies.
Oelke M; Weiss JP; Mamoulakis C; Cox D; Ruff D; Viktrup L
World J Urol; 2014 Oct; 32(5):1127-32. PubMed ID: 24504761
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study.
Zhang Z; Li H; Zhang X; Dai Y; Park HJ; Jiann BP; Li P; Lou Y; Ye Z; Viktrup L
Int J Urol; 2019 Feb; 26(2):192-200. PubMed ID: 30362173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
